Tell me about the TP53 mutation biomarker and what it means for my treatment options

TP53 Mutation in Marlo's Case: What It Means

I've reviewed your [ID removed] carefully, and I want to give you an honest answer: I don't see a TP53 mutation documented in the pathology reports, genetic testing, or molecular analysis that's been shared with me so far.

Here's what I do see in your records:

What Your Genetic Testing Shows

From your exome and whole genome sequencing:

• Your germline (inherited) genetic testing came back negative for clinically significant variants
• Your tumor molecular testing showed:
  • Negative for OncoKids panel (which screens for cancer-related genes)
  • Negative for clinically significant gene fusions
  • Negative for copy number abnormalities (CMA)

The key finding in your case is different:

• Your tumor appears to have an EGFR mutation (ITD/KDD - internal tandem duplication/kinase domain duplication), which is unusual and important for treatment planning

Why This Matters

The absence of a TP53 mutation in your records is actually potentially favorable because:

1. TP53 mutations are associated with more aggressive tumor behavior and worse prognosis in many cancers
2. Your tumor's genetic profile appears more limited, which may make it more targetable with specific therapies
3. Your team is focusing on the EGFR alteration as the primary therapeutic target

Important Questions to Ask Your Oncology Team

Since you're asking about TP53 specifically, here are clarifying questions:

1. "Has TP53 been tested in my tumor tissue, and if so, what were the results?" (Sometimes testing is done but not highlighted in summary reports)
2. "Are there any other tumor suppressor genes that were tested that I should know about?"
3. "How does the absence of TP53 mutation affect my prognosis compared to other spindle cell sarcomas?"
4. "Should we be concerned about TP53 given my family history?" (This would be relevant if there's a family history of cancer)

What We're Actually Focusing On

Based on your records, your treatment strategy is centered on:

• EGFR ITD/KDD targeting (with drugs like afatinib being considered)
• Comprehensive molecular profiling through organoid and PDX models
• Potential combination approaches (like adding MET inhibitors)
• Immunotherapy strategies (vaccine development, CAR-T consideration)

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

If you have a specific reason for asking about TP53 (perhaps you saw it mentioned somewhere or have family history concerns), please let me know and I can help you prepare better questions for your care team!